PD1 Integrated Anti-PSMA CART in Treating Patients With Castrate-Resistant Prostate Cancer
PD1-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer
Castrate-Resistant Prostate Cancer
DRUG: PD1-PSMA-CART cells
Incidence of toxicity graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events, All adverse events (AEs) will be listed and summarized. Summaries of laboratory data will include, at a minimum, treatment-emergent laboratory abnormalities. Summaries of AEs and laboratory abnormalities will be based on the All Treated analysis set., 28 days
Prostate specific antigen (PSA) response rate, proportion of patients with ≥50% PSA decline from baseline at any time point after therapy and maintained for ≥4weeks, 180 days|Radiographic response rate by RECIST 1.1 & PCWG3, Proportion of patients with a best response of either complete response or partial response, assessed using Prostate Cancer Working group3(PCWG3) response criteria \& Response Evaluation Criteria In Solid Tumors (RECIST) 1.1, 180 days|Number of persistent CART cells detected by Quantitative Real-time Polymerase Chain Reaction or flow cytometry, Number of persistent CART cells detected by Quantitative Real-time Polymerase Chain Reaction or flow cytometry, 180 days
Clinical trial for the safety and efficacy of Non-viral programmed cell death protein-1(PD1) integrated anti-prostate-specific-membrane-antigen(PSMA) chimeric antigen receptor T(CART) cells in the treatment of Refractory Castrate-Resistant Prostate Cancer(CRPC)